In the claims:

1-20. (Canceled)

21. (Currently amended) A method for inhibiting tumor growth in a subject bearing a tumor, which comprises administering to the subject a nucleotide sequence in a carrier, wherein the administered nucleotide sequence inhibits tumor angiogenesis in said subject and thereby inhibits growth of said tumor and ~~RNA encoding at least one anti-angiogenic protein or peptide in a carrier whereby the RNA is expressed and tumor growth is inhibited,~~ wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.

22. (Currently amended) The method of claim 21, wherein the nucleotide sequence ~~RNA~~ and carrier are administered via intravenous injection.

23. (Previously presented) The method of claim 21, wherein the carrier is a liposomal carrier.

24. (Previously presented) The method of claim 21, wherein the carrier is a cationic polymer carrier.

25. (Previously presented) The method of claim 21, wherein the carrier is a micelle carrier.

26. (Currently amended) A method for providing anti-angiogenic therapy to a subject in need thereof, which comprises administering by injection to the subject a nucleotide sequence in a carrier, wherein the administered nucleotide sequence inhibits angiogenic growth and ~~RNA encoding at least one anti-angiogenic protein or peptide in a carrier whereby the RNA is expressed and angiogenic growth is inhibited,~~ wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles and a combination thereof.

27. (Previously presented) The method of claim 26, wherein the injection is intravenous injection.

28. (Previously presented) The method of claim 26, wherein the injection is made into a tumor in the subject.

29. (Previously presented) The method of claim 26, wherein the carrier is a liposomal carrier.

30. (Previously presented) The method of claim 26, wherein the carrier is a cationic polymer carrier.

31. (Previously presented) The method of claim 26, wherein the carrier is a micelle carrier.

32. (Previously presented) The method of claim 21, further comprising administering nucleic acid encoding a tumor suppressor protein.

33. (Previously presented) The method of claim 32, wherein the tumor suppressor protein is p53.

34. (Previously presented) The method of claim 26, further comprising administering nucleic acid encoding a tumor suppressor protein.

35. (Previously presented) The method of claim 34, wherein the tumor suppressor protein is p53.

36-40. (Canceled)

41. (New) The method of claim 21, wherein said administration is into said tumor.